Provided by Tiger Trade Technology Pte. Ltd.

C4 Therapeutics, Inc.

1.84
+0.06003.37%
Pre-market: 1.83-0.0100-0.54%04:17 EST
Volume:700.36K
Turnover:1.30M
Market Cap:178.32M
PE:-1.10
High:1.90
Open:1.79
Low:1.78
Close:1.78
52wk High:3.65
52wk Low:1.09
Shares:96.91M
Float Shares:72.05M
Volume Ratio:0.73
T/O Rate:0.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6711
EPS(LYR):-1.5181
ROE:-59.98%
ROA:-23.20%
PB:1.15
PE(LYR):-1.21

Loading ...

C4 Therapeutics Grants Stock Options to New Employee as Inducement

Reuters
·
Yesterday

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Yesterday

C4 Therapeutics Grants Stock Options to New Employee as Inducement

Reuters
·
Jan 27

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jan 27

C4 Therapeutics Unveils Pipeline Strategy Focused on Protein Degraders for Oncology and Inflammatory Diseases

Reuters
·
Jan 20

Top C4 Therapeutics Executive Makes Notable Move With Company Shares

TIPRANKS
·
Jan 17

C4 Therapeutics Chief Medical Officer Leonard Reyno Reports Sale of Common Shares

Reuters
·
Jan 17

C4 Therapeutics’ Phase 2 Myeloma Trial Moves Forward, Setting Up a Key Catalyst for CCCC Investors

TIPRANKS
·
Jan 16

C4 Therapeutics Announces Plans to Advance Cemsidomide Through Phase 2 Trials, Initiate Combination Studies, and Expand Discovery Pipeline Targeting Inflammation and Neurodegenerative Diseases Through 2028

Reuters
·
Jan 14

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

GlobeNewswire
·
Jan 14

C4 Therapeutics Sets Up New Combination Trial in Multiple Myeloma: What Investors Should Watch

TIPRANKS
·
Jan 13

C4 Therapeutics Is Maintained at Overweight by Barclays

Dow Jones
·
Dec 18, 2025

U.S. RESEARCH ROUNDUP-Airbnb, Garrett Motion, Range Resources

Reuters
·
Dec 17, 2025

C4 Therapeutics Inc : TD Cowen Initiates Coverage With Buy Rating

THOMSON REUTERS
·
Dec 03, 2025

C4 Therapeutics Initiated at Buy by TD Cowen

Dow Jones
·
Dec 02, 2025

TD Cowen Initiates C4 Therapeutics at Buy

MT Newswires Live
·
Dec 02, 2025

C4 Therapeutics to Participate in Evercore Healthcare Conference

Reuters
·
Nov 25, 2025

C4 Therapeutics Files $400 Million Mixed Shelf

MT Newswires Live
·
Nov 22, 2025

C4 Therapeutics files $400M mixed securities shelf

TIPRANKS
·
Nov 22, 2025

C4 Therapeutics Inc Files for Mixed Shelf of up to $400 Mln - SEC Filing

THOMSON REUTERS
·
Nov 22, 2025